  Abbreviations, acronyms & symbols                                                                         
  ----------------------------------- --------------------------------------------------------- --- ------- ------------------------------------------------
  AS                                  = Aortic valve stenosis                                       LVEF    = Left ventricular ejection fraction
  ATP                                 = Adenosine triphosphate                                      LVH     = Left ventricular hypertrophy
  AV                                  = Atrioventricular                                            LVIDD   = Left ventricular internal diastolic diameter
  AVA                                 = Aortic valve area                                           LVMI    = Left ventricular mass index
  AVR                                 = Aortic valve replacement                                    PCI     = Percutaneous coronary intervention
  BMI                                 = Body mass index                                             PWTd    = Posterior wall thickness diameter
  BNP                                 = Brain natriuretic peptide                                   QTcd    = Corrected QT dispersion
  CABG                                = Coronary artery bypass grafting                             QTd     = QT dispersion
  DBP                                 = Diastolic blood pressure                                    SBP     = Systolic blood pressure
  ECG                                 = Electrocardiogram                                           SPSS    = Statistical Package for the Social Sciences
  EuroSCORE                           = European System for Cardiac Operative Risk Evaluation       STS     = Society of Thoracic Surgeons
  HR                                  = Heart rate                                                  TAVI    = Transcatheter aortic valve implantation
  IVSDT                               = Interventricular septum diastolic thickness                 VF      = Ventricular fibrillation
  LDL                                 = Low-density lipoprotein                                     VT      = Ventricular tachycardia

INTRODUCTION
============

Transcatheter aortic valve implantation (TAVI) has recently become an effective therapeutic alternative to surgical treatment for patients with severe symptomatic aortic valve stenosis (AS), particularly for those who were considered as high-risk surgical or inoperable patients. When compared with medical therapy alone, untreated severe AS has a high rate of morbidity and mortality^\[[@r1],[@r2]\]^. TAVI has been suggested to be more reliable in high-risk surgical or inoperable patients in recent studies^\[[@r3]-[@r6]\]^.

In patients with severe symptomatic AS, it has been postulated that malignant ventricular arrhythmias play a vital role in the outcomes and sudden cardiac death^\[[@r7]\]^.

QT dispersion (QTd) is the maximum inter-variance between the longest and shortest QT intervals recorded on a standard 12-lead electrocardiogram (ECG). It reflects the homogeneity of myocardial repolarization^\[[@r8]\]^. In addition, QTd can be used as a probable prognostic tool for future ventricular tachyarrhythmias and death^\[[@r9],[@r10]\]^.

Left ventricular hypertrophy (LVH) due to chronic pressure stress is a risk factor for ventricular arrhythmias and sudden cardiac death^\[[@r11]\]^. Increased QTd has been reported in AS patients and has also been shown to be a potential marker for ventricular arrhythmic homogeneity and mortality. QTd reduction by surgical aortic valve replacement (AVR) has also been reported^\[[@r8]\]^. For these reasons, I would like to investigate the effect of TAVI on QTd in patients with severe AS in this study.

METHODS
=======

Study Design and Patients
-------------------------

A total of 152 patients with severe AS were followed up prospectively. Ninety-five of these patients underwent AVR with TAVI method. Patients who were found to be suitable for TAVI by the heart team council of our center were included in the TAVI group. Patients who were suitable for surgical AVR were not included in the study. The study was conducted between June 2013 and December 2015. The patients who underwent AVR with TAVI were included in the TAVI group (n=95); the patients who refused TAVI were included in the medical treatment group (n=57). Patients who had atrial fibrillation or flutter, frequent (\> 10/min) ventricular extrasystoles, sinus or atrioventricular (AV) node dysfunction, permanent cardiac pacemaker, abnormal serum electrolyte levels, congenital long-QT syndrome, who had been taking any drugs influencing QTd and using antiarrhythmic drugs, with new bundle branch block, or who had become pacemaker dependents after TAVI were excluded. Operative risks for patients were calculated using the Logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) and the Society of Thoracic Surgeons (STS) Predictive Risk of Mortality scores. Patients with a Logistic EuroSCORE \>20% or an STS score \>10% were considered as high-risk patients.

Clinical, demographic, 12-lead ECG, and echocardiographic data, procedural variables, and morbidity and mortality rates were recorded for the first and sixth months and the first year following TAVI. First and sixth months and first year follow-up visits after the discharge of patients were performed at our center.

The study was approved by the institutional ethics committee, and all the study-related procedures were performed according to the latest version of the Helsinki Declaration. All patients signed an informed consent form prior to their participation in the study.

Electrocardiography
-------------------

Standard 12-lead ECG (25 mm/s) was recorded after a 10-minute rest in the supine position before TAVI and at the first and sixth months after TAVI. QTd calculation was manually performed by two independent cardiologists who were blinded to all patients' data. The compatibilities of QTd were statistically analyzed. If there was a difference between the results of QTd, the final decision was made by consensus. The QT interval was measured from the onset of the QRS complex to the end of the T wave. The mean of three consecutive interval measurements was used in the analysis. QTd was calculated as the difference between the longest and shortest QT interval measured in each individual ECG lead. QT intervals were corrected with Bazett's formula (QTc:QT√RR).

Echocardiography
----------------

Patients were evaluated with standard transthoracic M-mode and two-dimensional echocardiographic studies before and after TAVI procedure. Left ventricular diastolic and systolic dimensions and ventricular septal and posterior wall thicknesses were measured at the level of the tips of the mitral valve leaflet. Severe AS was described as a mean aortic valve gradient of ≥ 40 mmHg or an aortic valve area (AVA) of ≤ 1 cm^2^.

Study Procedures
----------------

A mean aortic gradient \>40 mmHg, an AVA \<1 cm^2^, and a valve area index (valve area/body surface area) \<0.6 cm^2^ were considered severe AS^\[[@r1]\]^. Edwards SAPIEN XT valve (Edwards Lifesciences, Irvine, California, USA) balloon-expandable device (n=85) and Medtronic CoreValve (MCV; Medtronic, Minneapolis, Minnesota, USA) self-expandable device (n=10) were used for TAVI. A vascular occlusion device (ProStar XL, Abbott Laboratories, North Chicago, Illinois, USA) was used in eligible patients in terms of femoral artery diameter and anatomy. The surgical cutdown method was applied in patients who were unsuitable for using the iliac and femoral artery vascular closure device. Transesophageal echocardiography and multislice computed tomography were done to determine the diameter of the aortic bioprosthesis. Patients received clopidogrel 75 mg, aspirin 100 mg, and intravenous antibiotherapy before the procedure.

Statistical Analysis
--------------------

Continuous variables were expressed as mean ± standard deviation and categorical variables were expressed as percentages. The normal distribution of values was assessed by using the Kolmogorov-Smirnov test and histogram. Paired *t*-test, independent sample t-test, and Wilcoxon-rank test were used for continuous variables, when appropriate. Pearson's or Spearman's correlation coefficient were used to assess the relationship between the parameters, when appropriate. A *P*-value \< 0.05 represented a statistically significant result. Statistical analysis was carried out using the Statistical Package for the Social Sciences (SPSS) software (SPSS Inc., Chicago, Illinois, USA), version 16.0.

RESULTS
=======

A total of 152 consecutive patients were enrolled in the study. TAVI was successfully performed in 47 (49.4%) women and 48 (50.6%) men without severe complications during the hospital stay and follow-up period. Demographic characteristics of the study population are presented in [Table 1](#t1){ref-type="table"} and basal echocardiographic and electrocardiographic characteristics in [Table 2](#t2){ref-type="table"}. The baseline demographic characteristics were similar in both groups. There was no difference in baseline echocardiographic, electrocardiographic, and other clinical parameters. No difference was found between these two groups' in basal QTd, corrected QT dispersion (QTcd), and other electrocardiographic measurements, like heart rate, PR interval, QRS duration, and QRS axis ([Table 2](#t2){ref-type="table"}). However, TAVI caused a significant reduction in the mean aortic valve gradient, QTd, and QTcd after six months ([Table 3](#t3){ref-type="table"}). In the sixth month after TAVI, mean aortic gradients, maximum and minimum QT times, QTd, and QTcd time were significantly decreased in the TAVI group, compared to the medical treatment group. Moreover, the QTd significantly decreased in the TAVI group after the TAVI procedure ([Table 4](#t4){ref-type="table"}). Mortality and arrhythmic complications were found to be smaller in the TAVI group at one-year follow-up than in the medical treatment group ([Table 5](#t5){ref-type="table"}).

###### 

Demographic and clinical characteristics of patients who underwent TAVI and medical treatment.

  ------------------------------------------------------------------
                       TAVI\        Medical treatment\   *P*-value
                       (n=95)       (n=57)               
  -------------------- ------------ -------------------- -----------
  Age (years)          78.1±7.3     80±6.5               0.675

  Male                 50(%52.6)    29(%50.8)            0.854

  BMI                  27.6±5.6     29.4±3.5             0.657

  HR                   78.3±9.4     80±8.6               0.346

  SBP                  129±25       135±15               0.435

  DBP                  82±14        78±22                0.358

  Previous CABG        28(%29.4)    18(%31.5)            0.254

  Previous PCI         36(%37.8)    21(%36.8)            0.342

  LVEF                 45.1±10.6    43.2±5.5             0.345

  Logistic EuroSCORE   33.4±10.9    35.5±9.4             0.375

  STS Score            13.5±6.5     14.5±7.5             0.554

  BNP                  7793±2450    6850±2850            0.455

  LDL                  135.4±27.2   142±32.5             0.550

  Triglyceride         145.2±35.1   152±25.5             0.650

  Hematocrit           36.2±5       34.5±6.5             0.385

  Creatine             1.21±0.55    1.42±0.40            0.545
  ------------------------------------------------------------------

BMI=body mass index; BNP=brain natriuretic peptide; CABG=coronary artery bypass grafting; DBP=diastolic blood pressure; EuroSCORE = European System for Cardiac Operative Risk Evaluation; HR=heart rate; LDL=low-density lipoprotein; LVEF=left ventricular ejection fraction; PCI=percutaneous coronary intervention; SBP=systolic blood pressure; STS=Society of Thoracic Surgeons; TAVI=transcatheter aortic valve implantation

###### 

Basal echocardiographic and electrocardiographic characteristics of patients in TAVI and medical treatment groups.

  Parameters             TAVI (n=95)   Medical treatment (n=57)   *P*-value
  ---------------------- ------------- -------------------------- -----------
  Heart rate             78.7±9.7      76.1±10.1                  0.872
  LVIDD                  52.1±5.9      50.8±5.1                   0.323
  IVSDT                  13.7±1.5      13.8±1.7                   0.860
  PWTd                   12.7±1.3      12.9±1.1                   0.761
  LVMI                   259.7±12.1    246±15                     0.145
  Mean aortic gradient   50.1±10.8     49.3±12.5                  0.689
  Max aortic gradient    86.2±11.5     83.6±14.2                  0.370
  Max QT                 443.7±61.7    445.2±51.8                 0.779
  Min QT                 350.2±30.2    352.3±34.8                 0.923
  QTd                    119.7±24.1    123.5±23.1                 0.096
  QTcd                   136.8±23.3    135.2±20.8                 0.679

IVSDT=interventricular septum diastolic thickness; LVIDD=left ventricular internal diastolic diameter; LVMI=left ventricular mass index; PWTd=posterior wall thickness diameter; QTcd=corrected QT dispersion; QTd=QT dispersion; TAVI=transcatheter aortic valve implantation

###### 

Hemodynamic, echocardiographic, and electrocardiographic characteristics of TAVI patients at baseline and the 6^th^ month after TAVI.

  Parameters             Before TAVI   6^th^month after TAVI   *P*-value
  ---------------------- ------------- ----------------------- -----------
  SBP                    129.2±21.1    127.8±22.6              0.655
  DBP                    75.4±9.5      79.2±13.8               0.635
  Heart rate             78.7±9.7      75.8±11.2               0.285
  LVIDD                  52.1±5.9      51.3±4.2                0.355
  IVSDT                  13.7±1.5      12.8±2.2                0.240
  PWTd                   12.7±1.3      12.3±1.7                0.205
  LVMI                   259.7±12.1    241±12                  0.230
  Mean aortic gradient   50.1±10.8     12.7±4.6                \<0.001
  Max aortic gradient    86.2±11.5     26±5.6                  \<0.001
  Max QT                 443.7±61.7    355±45                  \<0.001
  Min QT                 350.2±30.2    310±38                  \<0.001
  QTd                    119.7±24.1    105±27                  \<0.001
  QTcd                   136.8±23.3    110±24                  \<0.001

DBP=diastolic blood pressure; IVSDT=interventricular septum diastolic thickness; LVIDD=left ventricular internal diastolic diameter; LVMI=left ventricular mass index; PWTd=posterior wall thickness diameter; SBP=systolic blood pressure; QTcd=corrected QT dispersion; QTd=QT dispersion; TAVI=transcatheter aortic valve implantation

###### 

Hemodynamic, echocardiographic, and electrocardiographic characteristics of patients who underwent TAVI and medical treatment at the 6^th^ month.

  --------------------------------------------------------------------------------
  Parameters             TAVI\                  Medical treatment\     *P*-value
                         (at the 6^th^ month)   (at the 6^th^ month)   
  ---------------------- ---------------------- ---------------------- -----------
  SBP                    127.8±22.6             126.2±15.1             0.470

  DBP                    79.2±13.8              78.1±12.1              0.580

  Heart rate             75.8±11.2              74.2±10.5              0.390

  LVIDD                  51.3±4.2               50.2±3.8               0.385

  IVSDT                  12.8±2.2               13.7±2.8               0.375

  PWTd                   12.3±1.7               13.1±2.5               0.345

  LVMI                   241±12                 248±25                 0.350

  Mean aortic gradient   12.7±4.6               51.7±11.8              \<0.001

  Max aortic gradient    26±5.6                 86.7±15.5              \<0.001

  Max QT                 355±45                 457.3±52.1             \<0.001

  Min QT                 310±38                 358.8±31.7             \<0.001

  QTd                    105±27                 132.5±28.5             \<0.001

  QTcd                   110±24                 141.2±18.5             \<0.001
  --------------------------------------------------------------------------------

DBP=diastolic blood pressure; IVSDT=interventricular septum diastolic thickness; LVIDD=left ventricular internal diastolic diameter; LVMI=left ventricular mass index; PWTd=posterior wall thickness diameter; SBP=systolic blood pressure; QTcd=corrected QT dispersion; QTd=QT dispersion; TAVI=transcatheter aortic valve implantation

###### 

Mortality and arrhythmia complication rates at the end of one-year follow-up of the patients in the medical treatment group compared with the TAVI group.

  ------------------------------------------------------------------------------------------
  Parameters                                TAVI\           Medical treatment\   *P*-value
                                             (1^st^ year)   (1^st^ year)         
  ----------------------------------------- --------------- -------------------- -----------
  Mortality                                 6 (%6.3)        11 (%19.3)           0.015

  Total AV block (permanent or temporary)   9 (%9.5)        6(%10.5)             0.520

  Pacemaker implantation                    4 (%4.2)        4 (%7.0)             0.346

  Ventricular tachycardia                   6 (%6.3)        14 (%24.6)           0.002

  Ventricular fibrillation                  3 (%3.2)        8 (%14.0)            0.016
  ------------------------------------------------------------------------------------------

AV=atrioventricular; TAVI=transcatheter aortic valve implantation

DISCUSSION
==========

The number of patients with degenerative aortic valve disease is expected to rise in the future. And adults may remain asymptomatic for a long time^\[[@r12]\]^. After heart failure, syncope, and angina, the survival time is shortened^\[[@r1]\]^. Surgical AVR is now the gold standard treatment for patients with severe symptomatic AS. However, some severe symptomatic AS patients may present a very high risk for surgery due to contraindications or comorbidities. They cannot be operated on or are considered high risk for surgery. TAVI is a well-known alternative technique for these patients^\[[@r4],[@r13]\]^.

In patients with symptomatic AS, malignant ventricular arrhythmias play an important role in the development of syncope and sudden cardiac death^\[[@r14]\]^. Some studies have shown that ventricular arrhythmias are more frequent in these patients than in control subjects^\[[@r15]\]^. ECG of the patients before, during, and after syncope were investigated and malignant ventricular arrhythmia was detected during syncope.

QTd, which increases the formation of ventricular arrhythmias, can be calculated from the surface ECG reflecting regional heterogeneity of ventricular repolarization^\[[@r16]\]^. Many disorders, such as ventricular hypertrophy, myocardial ischemia, autonomic neuropathy, electrolyte imbalance, and use of antiarrhythmic drugs, can cause impaired repolarization and increased QTd.

In our study, we investigated the effect of TAVI on QTd in patients with symptomatic severe AS. We found out that QTd decreased in patients with severe AS who underwent TAVI at the sixth postprocedure month.

In our study, six patients (6.3%) died in the TAVI group and 11 (19.3%) patients died in the medical treatment group. One-year mortality was significantly lower in the TAVI group (*P*\<0.001) than in the medical treatment group. The ratio of ventricular tachycardia (VT) (*P*\<0.001) and ventricular fibrillation (VF) *(P*\<0.001) was significantly higher in the medical treatment group than in the TAVI group during Holter monitoring, outpatient visits, and emergency department admissions. In our study, QTd and QTcd time after AVR with TAVI method were significantly shorter than in the medical treatment group.

Arrhythmogenesis depends on the modulation of ion currents, abnormal ventricular structure, and myocardial ischemia^\[[@r17]\]^. Ventricular dilation and fibrosis may affect different regions of the ventricular wall and may cause an increase in the spread of refractory areas. The evidence of increased QTd in patients with hypertrophic cardiomyopathy, acquired forms of long QT syndrome, uremic neuropathy, hypertension in patients with myocardial infarction, and LVH supports the theorem above^\[[@r17]\]^. The effects of AVR on QTd were evaluated by two studies in the literature. Darbar et al.^\[[@r18]\]^ have shown that increased QTd after AVR in patients with significant AS is reduced. This finding was later reported by Orlowska-Baranowska et al.^\[[@r19]\]^. Patients with LVH were also reported to have had myocardial ischemia despite normal coronary angiograms. Thallium scans of patients with significant AS and normal coronary arteries often show perfusion deficits due to microvascular dysfunction^\[[@r20]\]^. Microvascular dysfunction leads to a marked remodeling of the cellular compartments of the myocardium. At the cellular level, studies have shown that adenosine triphosphate (ATP)-sensitive potassium channels are more likely to be opened during ischemia in hypertrophic myocytes compared to normal myocytes. This may prolong the repolarization of the myocardium allowing subsequent depolarisations and triggered activity that initiate ventricular arrhythmias^\[[@r21]\]^.

Another mechanism is the increased myocardial interstitial fibrosis in LVH and it has significant effects on electrical conduction^\[[@r22]\]^. Increased myocardial interstitial fibrosis, intraventricular conduction, and nonhomogeneous repolarization facilitate micro-reentry, and arrhythmia can lead to electrical abnormalities in electrical connections between myocardial fibers^\[[@r23]\]^.

In addition, the cardiac renin-angiotensin-aldosterone system activates the gene expression of collagen and fibronectin. This probably contributes to an increase in total collagen volume in the myocardium^\[[@r24]\]^. On the contrary, AS corrupts coronary blood flow. For this reason, hypertrophy and ischemic heart muscles may cause electrophysiological changes.

Previous studies have shown that heterozygosity in repolarization is a predisposed situation to life-threatening arrhythmias, such as VT and VF. The electrical imbalance of the heart muscle can be detected by QTd using surface ECG.

The recovery of autonomic functions appears to be another way of explaining the effect of TAVI on repolarization markers. Patients with severe AS have reported increased sympathetic nervous system activity and reduced sympathetic baroreflex gain. They also demonstrated normalization of sympathetic nervous system activity and restoration of arterial baroreflex gain after TAVI. Increased sympathetic activity has been shown to increase QT interval. It can be suggested that autonomic dysfunction may increase ventricular repolarization abnormalities and QTd. Mechanical obstruction is significantly reduced after TAVI procedure and cardiac output is increased. And this induces improvement of autonomic dysfunction.

Study Limitations
-----------------

Our study has some limitations. The small sample size was the main limitation. Coronary ischemia is improved after TAVI and can reduce fatal arrhythmias, but there was no objective criterion for its distinction; another limitation was that arrhythmia complications in both groups could not be determined exactly. Only in the first and sixth months, patients were evaluated by Holter monitoring. ECG controls were performed only in the third and sixth months and the first year in the outpatient clinic. However, apart from these periods, arrhythmic complications may have occurred.

CONCLUSION
==========

In our study, postprocedure changes in cardiac conduction times and intervals showed positive changes after TAVI. QTd is one of them. According to the results of our study, QTd is more closely related to mortality and malignant arrhythmias in patients with severe AS treated medically than patients who underwent TAVI. It was determined that mortality and malignant arrhythmia rates were reversed with positive changes in QTd after TAVI.

Long-term recording is therefore better for assessing the incidence of ventricular arrhythmias in these patients. For this reason our results should be confirmed with further studies to determine the effectiveness of TAVI on arrhythmic mortality and morbidity.
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